Physician profile
Jon Staffel
NPI 1437114790
$923.94
in general payments reported to CMS, 2019-2025
11 companies · $464 in 2025
The $464 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.56 · 2021: $29.76 · 2022: $164 · 2023: $29.07 · 2024: $186 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $313.99 | 2022-2025 | Nucala |
| Medtronic, INC. | $151.56 | 2024 | Propel |
| Genzyme Corporation | $102.58 | 2025 | |
| Optinose US, INC. | $89.08 | 2019-2022 | |
| Stryker Corporation | $71.70 | 2022 | |
| Aerin Medical INC. | $57.37 | 2022-2025 | |
| Abbvie INC. | $40.27 | 2022 | |
| Hikma Pharmaceuticals USA | $34.08 | 2024-2025 | Ryaltris |
| Merck Sharp & Dohme LLC | $29.09 | 2021-2023 | |
| Inspire Medical Systems, INC. | $22.50 | 2025 | Inspire |
| Neurent Medical Limited | $11.72 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Staffel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.